Protara Therapeutics (NASDAQ:TARA) Receives Buy Rating from HC Wainwright

Protara Therapeutics (NASDAQ:TARA)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They presently have a $23.00 price objective on the stock.

Separately, Oppenheimer boosted their price target on Protara Therapeutics from $26.00 to $30.00 and gave the stock an “outperform” rating in a research report on Monday, April 22nd.

Protara Therapeutics Stock Down 1.0 %

NASDAQ:TARA opened at $2.87 on Monday. The firm has a market capitalization of $32.80 million, a P/E ratio of -0.77 and a beta of 1.80. Protara Therapeutics has a 52 week low of $1.04 and a 52 week high of $5.24. The company has a fifty day moving average of $3.57 and a 200 day moving average of $2.56.

Protara Therapeutics (NASDAQ:TARA) last announced its earnings results on Wednesday, March 13th. The company reported ($0.90) EPS for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.13. As a group, analysts anticipate that Protara Therapeutics will post -3.55 EPS for the current year.

Hedge Funds Weigh In On Protara Therapeutics

An institutional investor recently bought a new position in Protara Therapeutics stock. Oppenheimer & Co. Inc. bought a new position in Protara Therapeutics, Inc. (NASDAQ:TARA) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 10,000 shares of the company’s stock, valued at approximately $40,000. Oppenheimer & Co. Inc. owned about 0.09% of Protara Therapeutics as of its most recent filing with the Securities & Exchange Commission. 38.13% of the stock is owned by institutional investors.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.